What Is Wegovy?

1. What Is Wegovy?

Wegovy is a prescription semaglutide brand from Novo Nordisk. The current DailyMed Wegovy label describes Wegovy as a glucagon-like peptide-1, or GLP-1, receptor agonist and lists both Wegovy injection and Wegovy tablets.

The official Wegovy site also presents Wegovy as a brand with multiple forms, including a pill and pen-based products. That matters because older public shorthand often treated Wegovy as simply “the weekly semaglutide weight-loss shot.” In current U.S. sources, that shortcut is incomplete.

The useful plain-language answer is this: Wegovy is semaglutide under a Wegovy-specific brand label. To understand what someone means, you still need the route, the labeled context, and the source being used.

2. What Is Semaglutide?

Semaglutide is the active ingredient in Wegovy. It is also the active ingredient in other brand contexts, including Ozempic and Rybelsus. That shared molecule is the reason the names are so easy to blur, but molecule identity does not make the brand labels interchangeable.

The Wegovy label describes semaglutide as a GLP-1 receptor agonist. GLP-1 stands for glucagon-like peptide-1, a hormone involved in glucose and appetite signaling. GLP-1 receptor agonist medicines are designed to act on related receptor pathways; they are not simply the body’s natural GLP-1 hormone in a vial or tablet.

This separation is the key to most Wegovy confusion:

For broader class background, see What Is a GLP-1?. For semaglutide-specific background, see What Is Semaglutide?.

3. Why Is Wegovy Mostly a Weight-Management Story?

Wegovy became widely known because its original U.S. weight-management approval was tied to obesity and overweight with weight-related conditions. FDA’s June 2021 consumer update said Wegovy injection was approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, used with reduced calorie diet and increased physical activity (FDA June 2021 update).

That approval is why Wegovy sits in a different public lane than Ozempic. Ozempic is strongly associated with type 2 diabetes labeling. Wegovy is strongly associated with weight management, even though both names involve semaglutide.

The current DailyMed label is more detailed than the original public story. It lists Wegovy injection for long-term weight reduction in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition. It lists Wegovy tablets for long-term weight reduction in adults with obesity or adults with overweight plus at least one weight-related comorbid condition.

That is a label summary, not an eligibility checklist. This page does not interpret BMI, comorbidities, age, symptoms, insurance coverage, or whether Wegovy is appropriate for any person.

4. Where Does Heart-Risk Reduction Fit?

In March 2024, FDA approved a Wegovy injection indication to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight (FDA cardiovascular-risk announcement).

That was a meaningful label expansion because it moved Wegovy beyond a weight-management-only headline. FDA described it as the first weight-loss medication also approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight.

The FDA announcement said the cardiovascular outcomes trial randomly assigned more than 17,600 participants to Wegovy or placebo. Major adverse cardiovascular events occurred in 6.5% of participants who received Wegovy compared with 8% of participants who received placebo. The current DailyMed label also includes cardiovascular-risk-reduction indications for Wegovy injection and Wegovy tablets in adults with established cardiovascular disease and either obesity or overweight.

Those are population and label facts. They do not predict an individual outcome, replace a cardiovascular evaluation, or answer whether a person should start, stop, continue, or switch any medication.

5. What Changed With Wegovy Tablets?

The big change is that Wegovy is no longer only an injection brand in current official materials. The official Wegovy site says Wegovy is now a once-daily pill and describes it as the only FDA-approved semaglutide tablet for weight loss in adults. DailyMed lists Wegovy tablets alongside Wegovy injection under the Wegovy label.

Novo Nordisk announced in December 2025 that FDA had approved once-daily Wegovy pill as an oral GLP-1 medicine for obesity in the United States, with weight-management and cardiovascular-risk-reduction contexts in adults (Novo Nordisk announcement via PR Newswire).

The practical communication point is simple: “Wegovy” can now mean injection or tablet. A careful article, chart, medication list, or record treats route as a label detail, not something the brand name alone settles.

The label includes route-specific instructions and switching language, but this article intentionally does not summarize those instructions. That level of detail belongs in prescribing information and clinician-guided care, not in a general explainer.

6. What Other Label Contexts Are Easy to Miss?

Wegovy’s label has grown beyond the public shorthand. In addition to weight reduction and cardiovascular-risk reduction, FDA announced in August 2025 that Wegovy injection was approved to treat metabolic dysfunction-associated steatohepatitis, or MASH, in adults with moderate-to-advanced fibrosis, under accelerated approval (FDA MASH announcement).

MASH is a liver-disease context, not a casual synonym for weight loss. FDA said continued approval for that indication may depend on verification and description of clinical benefit in a confirmatory trial. DailyMed’s indications section also frames the MASH context for Wegovy injection rather than for every Wegovy presentation.

This is why the label source matters. A media story may say “Wegovy is for weight loss,” while the current label includes more nuance. The right answer depends on whether the question is about the molecule, the brand, the route, the indication, the population, or the year of the source.

7. Wegovy, Ozempic, and Rybelsus Are Related but Different

Wegovy, Ozempic, and Rybelsus are all semaglutide brand contexts, but the brands do different work in public language and in labeling. A high-level map helps:

The confusion is understandable. People hear “semaglutide” and then see multiple famous names. They hear “pill” and think only of Rybelsus. They hear “weight loss” and think only of Wegovy. Then official sources change, and older shorthand becomes stale.

For more on Ozempic specifically, see What Is Ozempic?. For recordkeeping context rather than medication selection, see Wegovy Tracker App or Semaglutide Tracker App.

8. How to Read Wegovy Information Without Mixing Up the Facts

The safest way to read Wegovy information is to separate six fields before drawing any conclusion:

This field-based reading prevents a common mistake: treating one correct fact as the whole story. “Wegovy contains semaglutide” is correct. “Ozempic contains semaglutide” is also correct. But those two facts do not collapse Wegovy, Ozempic, and Rybelsus into one product.

It also protects against another mistake: turning label updates into personal conclusions. Current labels can explain what a product is approved for, what forms are listed, and what warnings exist. They still do not settle person-specific use questions in isolation.

9. Sources

10. What Is Wegovy FAQ

• What is Wegovy in simple terms?

  Wegovy is a Novo Nordisk brand name for prescription semaglutide products. Current U.S. labeling includes Wegovy injection and Wegovy tablets, with weight-management and cardiovascular-risk-reduction contexts that differ from Ozempic and Rybelsus.

• Is Wegovy the same thing as semaglutide?

  No. Semaglutide is the active ingredient. Wegovy is a brand name attached to specific U.S. labels. Ozempic and Rybelsus also involve semaglutide, but the brand, route, and indicated-use context are different facts.

• Is Wegovy a shot or a pill?

  Current official sources describe both Wegovy injection and Wegovy tablets. That does not mean every Wegovy product has the same route, patient population, label details, or instructions.

• How is Wegovy different from Ozempic and Rybelsus?

  At a high level, Wegovy is semaglutide branding centered on weight management and related labeled contexts. Ozempic is semaglutide branding centered on type 2 diabetes, and Rybelsus is oral semaglutide branding for type 2 diabetes.